Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 15, 2011

View Archived Issues

New model developed to evaluate pharmacodynamics of antimicrobial agents and design dosing regimens

Phase III data presented on long-term safety and tolerability of degarelix in prostate cancer

Novartis profiles achievements of 2010

Lucentis improves vision in patients with diabetic macular edema in phase III RISE trial

Oxigene and NCI collaborate on phase II Zybrestat trial in ovarian cancer

Enrollment begins in Diamyd's phase II NP2 enkephalin trial in cancer pain

Ginseng metabolite S-111 has potent antidepressant effects in vivo

SMB recommends continuation of Vical's phase III Allovectin-7 trial in metastatic melanoma

Abbott identifies novel inhibitors of Cdc7

Gold nanoshells with silica nanorattle cores combine photo- and chemotherapy to treat cancer

Axcan Pharma acquires Eurand

DMC recommends continuation of phase III ThermoDox HEAT trial

Bayer Schering claims new [18F]-labeled PET imaging agents

Novel autotaxin inhibitors claimed

Beta Pharma patents new activators of hypoxia-inducible factor 1

Kamada receives interim report of phase II/III trial of inhaled alpha-1 antitrypsin

NurOwn autologous adult stem cell product receives FDA orphan drug status in ALS

PROLOR's phase II trial of long-acting human growth hormone proceeds as planned

Polaris and LICR begin phase II trial of ADI-PEG 20 in SCLC

Tarsa completes phase III trial of oral calcitonin in osteoporosis

Marina Biotech provides update on development of oligonucleotide-based therapeutics

Endpoint met in first part of phase II trial of Reolysin and gemcitabine in pancreatic cancer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 4, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 4, 2025.
UK Biobank delivers largest metabolomics dataset of 500K profiles
BioWorld Science
It’s the biological resource that keeps on giving, and now UK Biobank has released the final tranche of data on the levels of 249 metabolites in the blood of its...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...